COMP <GO>
HAE vs MMED // NET PROFIT MARGIN
Haemonetics Corporation (NYSE) VS. MiniMed Group Inc. (NASDAQ) • 15-METRIC TALLY: HAE 8
— MMED 3
▲ NET PROFIT MARGIN LEADER: HAE
LAST: $120.14 (+0.41%) • MKT CAP: $5.44B
net-margins
0.00%
LAST: $18.90 (+3.39%) • MKT CAP: $5.14B
net-margins
-10.70%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (HAE VS. MMED)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | HAE | MMED | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 59.00% | 54.20% | +4.80 | HAE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 8.40% | -3.90% | +12.30 | HAE | /roic <GO> |
| EV/EBITDA & P/E Valuation | 32.5x | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | 4.78% | -7.75% | +12.53 | HAE | /fcf-yield <GO> |
| Operating Margin | 11.70% | -6.10% | +17.80 | HAE | /operating-margins <GO> |
| Net Profit Margin ACTIVE | 0.00% | -10.70% | +10.70 | HAE | /net-margins <GO> |
| Revenue Growth (YoY) | -2.00% | 14.30% | -16.30 | MMED | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 3.89 | 4.82 | -0.93 | MMED | /balance-sheet <GO> |
| Piotroski F-Score Quality | 7/9 | 5/9 | +2.00 | HAE | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 63.0 | 44.5 | +18.50 | HAE | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 1.00 | 1.05 | -0.05 | MMED | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | 24.0x | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $5.44B | $5.14B | $300.6M | HAE | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | HAE REV | MMED REV | HAE GROSS % | MMED GROSS % | HAE FCF | MMED FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $1.33B | $3.10B | 59.0% | 54.2% | $260.4M | -$420.0M |
| FY 2024 | $1.36B | $2.71B | 55.0% | 56.3% | $142.4M | -$53.0M |
| FY 2023 | $1.31B | $2.47B | — | — | $122.8M | -$70.1M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
HAE // BETA 1.00
MMED // BETA 1.05